Claims
- 1. A method of lowering the intraocular pressure in a human having abnormally high intraocular pressure, comprising
- administering thereto an amount of melatonin effective to lower the intraocular pressure.
- 2. A method as claimed in claim 1 wherein the human has glaucoma.
- 3. A method as claimed in claim 1 wherein melatonin is administered in a circadian manner.
- 4. A method as claimed in claim 1 wherein the melatonin is administered orally.
- 5. A method as claimed in claim 1 wherein the melatonin is administered topically.
- 6. A method as claimed in claim 1 wherein the amount of the melatonin administered is from about 0.30 to 170.0 mg/kg/day.
- 7. A method of lowering the intraocular pressure in a human having abnormally high intraocular pressure, comprising administering melatonin orally on successive days, in an amount from about 3.3 to 16.7 mg/kg/day, to a human being having glaucoma.
Government Interests
This invention was made with Government Support under contract #5 RO1 MH40161-02 awarded by the National Institute of Mental Health. The government has certain rights in this invention.
US Referenced Citations (5)
Foreign Referenced Citations (1)
Number |
Date |
Country |
78431 |
May 1983 |
EPX |
Non-Patent Literature Citations (3)
Entry |
Chem. Abst. 102:933f (1985)--Chiou et al. |
Chem. Abst. 104:29256q (1986)--Chiou et al. |
Chem. Abst. 104:82662v (1986)--Rohde et al. |